Table 2.
p value | drug | target |
---|---|---|
5.7 × 10−5 | GSK461364 | polo-like kinase, active in M phase |
0.00031 | docetaxel | mitotic spindle |
0.00065 | vinorelbine | mitotic spindle |
0.0025 | paclitaxel | mitotic spindle |
0.0036 | etoposide | topoisomerase |
0.0039 | ibandronate | inhibits bone resorption |
0.0051 | bosutinib | tyrosine kinases |
0.0052 | ixabepilone | mitotic spindle |
0.019 | GSK923295 | centromere-associated protein |
0.022 | PF_3814735 | Aurora kinase, chromatid segregation |
0.023 | lestaurtinib | tyrosine kinases |
0.027 | TCS2312 | checkpoint kinase inhibitor |
0.028 | irinotecan | topoisomerase |
0.031 | XRP44X | ras-net (ELK3) |
0.033 | sunitinib | receptor tyrosine kinases |
0.035 | cisplatin | DNA |
0.043 | GSK1070916 | Aurora kinase, chromatid segregation |
0.049 | IKK_16 | IkB kinase |
For each drug, two-sample t tests were performed comparing drug sensitivity of the claudin-low cell lines to the others. The results were sorted on the p values.